The US Therapeutic Drug Monitoring Market was valued at $857.4 Million in 2024 and projected to reach to $1275.1 Million by 2029, representing a compound annual growth rate of 8.3%. The US Therapeutic Drug Monitoring market is poised for sustained expansion through 2029, driven by healthcare system modernization and increased focus on precision medicine.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US Therapeutic Drug Monitoring market is valued at $857.4 million in 2024, with strong growth trajectory reaching $1,275.1 million by 2029, representing an 8.3% CAGR.
US healthcare providers are increasingly implementing personalized medicine approaches, driving demand for TDM services to optimize drug dosing and improve patient outcomes across diverse populations.
Rising prevalence of chronic diseases in the US population necessitates continuous drug level monitoring, particularly for immunosuppressants, anticonvulsants, and cardiac medications requiring therapeutic optimization.
US clinical laboratories are investing in advanced automation technologies and integrated testing platforms, enhancing TDM efficiency, reducing turnaround times, and improving diagnostic accuracy.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | ONCOLOGY (Therapeutic Area) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 8.4% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 2.3 (2024) |
| Revenue Forecast (Billions) | ~USD 3.44 (2029) |
| Segments Covered | Product, Type, Technology, Drug Class, Therapeutic Area, Specimen, End User |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| COMMERCIAL & PRIVATE LABORATORIES | 299.4 | 317.6 | 338.1 | 361.1 | 386.4 | 414.5 | 445.7 | 480.6 | 7.3 |
| HOSPITAL LABORATORIES | 490.9 | 527 | 567.7 | 613.6 | 664.3 | 720.9 | 784.3 | 855.3 | 8.5 |
| OTHER END USERS | 132 | 138.6 | 146.1 | 154.5 | 163.6 | 173.8 | 185 | 197.5 | 6.2 |
| TOTAL | 922.4 | 983.3 | 1051.9 | 1129.2 | 1214.3 | 1309.1 | 1415 | 1533.3 | 7.8 |
The US Therapeutic Drug Monitoring market was valued at $857.4 million in 2024 and is expected to grow to $1,275.1 million by 2029.
The US TDM market is projected to grow at a compound annual growth rate (CAGR) of 8.3% from 2024 to 2029.
In the US, TDM is primarily driven by immunosuppressant monitoring in transplant patients, anticonvulsant therapy optimization, and cardiovascular drug level management.
Key growth drivers in the US include personalized medicine adoption, increasing chronic disease prevalence, laboratory automation advancements, and strong reimbursement support.
US laboratories are investing in high-throughput testing platforms, point-of-care devices, and integrated digital solutions to improve turnaround times and clinical outcomes.
The study involved major activities in estimating the current market size for the therapeutic drug monitoring market. Exhaustive secondary research was done to collect information on the therapeutic drug monitoring industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the therapeutic drug monitoring market.
The market for the companies offering therapeutic drug monitoring solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the blockchain market. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also conducted to identify the segmentation types, industry trends, competitive landscape of therapeutic drug monitoring solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.
In the complete market engineering process, the top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
*C-level primaries include CEOs, CFOs, COOs, and VPs.
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Therapeutic drug monitoring (TDM) measures the concentration of specific drugs in body fluids, which helps manage drug therapy to cure, alleviate, or prevent diseases. TDM is used mainly for monitoring drugs with narrow therapeutic ranges, drugs with marked pharmacokinetic variability, medications for which target concentrations are difficult to monitor, and drugs known to cause therapeutic and adverse effects.
Full forecast, segment splits, and company analysis for all Therapeutic Drug Monitoring Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report